Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 11:37:55 2024-05-10 EDT			5-day change	1st Jan Change
28.96 ^EUR	+0.92%		+3.34%	-13.90%

05-10	Strong TV ratings for RTL for Leverkusen's run to the final	DP
05-09	War upends Ukraine's economy in a shift that may be permanent	RE

BAYER AG : Morgan Stanley reiterates its Neutral rating

July 21, 2023 at 07:43 am

Analyst James Quigley from Morgan Stanley research gives the stock a Neutral rating. Previously set at EUR 60, the target price is lowered to EUR 57.

Latest news about Bayer AG

Strong TV ratings for RTL for Leverkusen's run to the final	05-10	DP
War upends Ukraine's economy in a shift that may be permanent	05-09	RE
Bayer to present new data at ACOG	05-08	CF
Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause	05-08	CI
Companies take a stand against extremism and racism	05-07	DP
BAYER AG : UBS sticks Neutral	05-06	ZD
Singtel Taps Head of Australia's Broadband Operator for Optus -- Update	05-05	DJ
Singtel-owned Optus names broadband network boss Stephen Rue as new CEO	05-05	RE
Singtel Taps Australian National Broadband Network CEO to Head Optus	05-05	DJ
European Equities Close Mostly Lower in Thursday Trading; Eurozone Manufacturing Remains in Contraction	05-02	MT
Manufacturing Downturn Keeps German Stocks Lower	05-02	MT
BridgeBio Pharma Shares Decline After Q1 Financial Results	05-02	MT
BAYER AG : Barclays reiterates its Neutral rating	05-02	ZD
Bayer Shares Surge After Monsanto Appeal Win	05-02	DJ
Bayer at high since early April after US court victory	05-02	DP
Jefferies rates Bayer a 'Hold' - Target 29 euros	05-02	DP
Bayer: Monsanto wins U.S. appeal	05-02	CF
European shares struggle for direction in earnings tide, Fed decision	05-02	RE
BAYER AG : Jefferies gives a Neutral rating	05-02	ZD
US Ruling Requires Bayer to Face Antitrust Lawsuit Over Flea Treatment	05-02	MT
US Court Overturns $185 Million PCB Contamination Verdict Against Bayer's Monsanto	05-01	MT
Bayer's Monsanto wins reversal of $185 million PCBs verdict in Washington court	05-01	RE
BAYER : Another year of patience needed	05-01
Bayer: strategic collaboration with Evotec	04-30	CF
Evotec, Bayer to Collaborate on New Cardiovascular Disease Therapies	04-30	MT

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q1 2024 Earnings Release

Related indices

EURO STOXX 50 , STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

BAYER : Another year of patience needed

May 01, 2024 at 11:38 am

Bayer AG: Not out of the woods yet

March 06, 2024 at 10:46 am

More Strategies

Ratings for Bayer AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

28.96 EUR

Average target price

36.9 EUR

Spread / Average Target

+27.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAYER AG	-13.90%	30.64B
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals

Bayer AG

Equities

BAYN

DE000BAY0017

Pharmaceuticals

BAYER AG : Morgan Stanley reiterates its Neutral rating

Latest news about Bayer AG

Chart Bayer AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Bayer AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals